Dialog Box

Skin Health Institute

Clinical Trials Now Recruiting

These study descriptions are intended for potential study participants. Study descriptions for clinicians can be found here.  

If you would like to learn more about any of the studies currently being conducted at the Skin Health Institute, please contact the nominated study coordinator.

If you have any general questions regarding the clinical trials conducted at the Institute, please feel free to contact the Clinical Trials Department at trials@skinhealthinstitute.org.au or by phone on (03) 9623 9439.

CHRONIC ATOPIC DERMATITIS RESEARCH STUDY (66 WEEKS)

Adults aged 18 years or older (weighing 40kg or more) with chronic atopic dermatitis (AD) present for 1 year or more, may qualify to receive investigational medication (active study drug) or placebo, via subcutaneous injection. 

To be eligible, participants must have moderate to severe atopic dermatitis with AD involvement of 10% or greater body surface area.  A history of inadequate response to treatment with topical medications, or determination that topical treatments are otherwise medically inadvisable, is also required.  Eligible participants will have regular visits with an experienced research team.  There is no cost to participate, and participants will be reimbursed for certain study-related expenses.

Individuals will be asked to visit the study centre about 19 times over a period of about 66 weeks.

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Charlie Wang
9623 9464
cwang@skinhealthinstitute.org.au

Study Coordinator
Charlotte Harrison-Mullan
9623 9470
charrison@skinhealthinstitute.org.au

Research study for Atopic Dermatitis (27 Weeks)

Males and females aged 18-75 with a documented history of chronic eczema/atopic dermatitis (AD) for at least 1 year, may qualify to receive investigational medication (active study drug) or placebo, via injection. Atopic Dermatitis is a chronic inflammatory skin disease commonly referred to as eczema.

To be eligible, participants must have a body mass index between 19 and 40 kg/m2 inclusive. Individuals must have moderate to severe disease severity, with AD that affects ≥ 10% of the body surface area. A documented history (within the past 6 months) of inadequate response to topical medications (corticosteroids) for AD, intolerance to treatment with topical medications for AD, or for whom topical medications are otherwise medically inadvisable, is also required. Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 12 times over a period of about 27 weeks.

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Charlie Wang
9623 9464
cwang@skinhealthinstitute.org.au

Study Coordinator
Charlotte Harrison-Mullan
9623 9470
charrison@skinhealthinstitute.org.au

Research Study for atopic dermatitis 

Adults aged 18 years or older with chronic atopic dermatitis (AD) for at least 2 years, may qualify to receive investigational medication (active study drug) or placebo.

To be eligible, participants must have moderate to severe AD with pruritus (itch), involving 10% of their body surface area. A history of inadequate response to treatment with topical medications (topical corticosteroids with or without topical calcineurin inhibitors) is also required. Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Length of study participation will vary per person as well as the number of visits to the study centre.

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Charlie Wang
9623 9464
cwang@skinhealthinstitute.org.au

Study Coordinator
Irina Danilovich
9623 9448
e: idanilovich@skinhealthinstitute.org.au

ATOPIC DERMATITIS CLINICAL STUDY (25 WEEKS)

Adults of legal age with a clinical diagnosis of chronic atopic dermatitis (AD) that has been present for at least 3 years, may qualify to receive investigational medication (active study drug) or placebo via subcutaneous injection.   

To be eligible, participants must have moderate to severe AD, with disease that affects ≥ 10% body surface area.  A history of inadequate response to a stable (≥ 1 month) regimen of topical corticosteroids or calcineurin inhibitors as treatment for AD within 3 months before the screening visit, is also required.  Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses. 

Study participation will last approximately 25 weeks and involve up to 23 visits to the study centre. 

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Charlie Wang
9623 9464
cwang@skinhealthinstitute.org.au

Study Coordinator
Charlotte Harrison-Mullan
9623 9470
charrison@skinhealthinstitute.org.au

Research study for Atopic dermatitis (34 weeks)

Females and males aged 18+ with a diagnosis of chronic atopic dermatitis (AD) for at least 1 year, may qualify to receive investigational oral medication (active study drug) with a placebo injection, or approved therapy via injection with a placebo tablet.   

To be eligible, participants must have moderate to severe AD, with disease that affects ≥ 10% body surface area.  A documented history (within the past 6 months) of inadequate response to topical medications for AD (for at least 4 consecutive weeks), or who have required systemic therapies for control of their disease within the past year, is also required.  Eligible participants will have regular visits with an experienced research team.  There is no cost to participate, and participants will be reimbursed for study-related expenses. 

Study participation will last about 34 weeks and involve about 10 visits to the study centre, plus 2 phone visits. 

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Charlie Wang
9623 9464
cwang@skinhealthinstitute.org.au

Study Coordinator
Tracy Mallet
9623 9406
tmallet@skinhealthinstitute.org.au

Research Study for Alopecia areata (26 months)

Adults aged 18 years or older with a clinical diagnosis of alopecia areata (hair loss), may qualify to receive investigational oral medication (active study drug).

To be eligible, participants must have 25% or more hair loss of the scalp, without evidence of terminal hair regrowth within 6 months. Current episode of hair loss must have occurred within 10 years. Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.                              

Study participation will last approximately 26 months and involve up to 13 visits to the study centre.                             

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Charlie Wang
9623 9464
cwang@skinhealthinstitute.org.au

Study Coordinator
Tracy Mallet
9623 9406
tmallett@skinhealthinstitute.org.au

RESEARCH STUDY FOR NAIL FUNGUS (Topical)

Adults aged between 18 and 65 years with onychomycosis (nail fungus), may qualify to receive investigational medication (active study drug) or placebo, via a topical solution that will be brushed on to the infected toe. 

To be eligible, participants must have a fungal toenail infection on at least one big toe, and also be in good health based on past medical history and physical examination as determined by the research doctor at the screening visit. Eligible participants will have regular visits (onsite and phone calls) with an experienced research team.  There is no cost to participate, and participants will be reimbursed for study-related expenses.

Length of study participation will be up to 40 weeks.

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Charlie Wang
9623 9464
cwang@skinhealthinstitute.org.au

Study Coordinator
Sarah Chivers
9623 9465
schivers@skinhealthinstitute.org.au

HIDRADENITIS SUPPURATIVA RESEARCH TRIAL (71 WEEKS)

Adults aged 18 years or older with a diagnosis of hidradenitis suppurativa (HS) for at least 6 months, may qualify to receive investigational medication (active study drug) or placebo, via injection.                           

To be eligible, participants must have HS lesions present in at least 2 distinct areas of the body. Moderate to severe disease with at least 5 inflammatory nodules or abscesses, must be present. Inadequate response to a course of a systemic antibiotic for the treatment of HS, is also required. Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 28 times over a period of about 71 weeks. 

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Charlie Wang
9623 9464
e: cwang@skinhealthinstitute.org.au

Study Coordinator
Irina Danilovich
9623 9448
e: idanilovich@skinhealthinstitute.org.au

RESEARCH STUDY FOR HIDRADENITIS SUPPURATIVA 

Adults aged 18-75 years old with a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least one year, may qualify to receive investigational oral medication (active study drug) or placebo. Participants must agree to use topical antiseptics daily, during study participation.

To be eligible, participants must have HS lesions present in at least 2 distinct areas of the body, with at least 4 inflammatory nodules or abscesses present. Inadequate response to at least a 4-week (28 day) trial of an oral antibiotic for the treatment of HS, is also required. Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 10 times over a period of about 26 weeks.

For more information, please contact:

Principal Investigator:
A/Prof Peter Foley

Sub Investigator:
Dr Charlie Wang
t: 9623 9400
e: cwang@skinhealthinstitute.org.au

Study Coordinator:
Irina Danilovich
t: 9623 9448
e: idanilovich@skinhealthinstitute.org.au


How do I become involved in a clinical trial at the institute?

Anyone can participate in a clinical trial. A referral from a doctor is not necessary.

Contact the Clinical Trials Department directly to inquire about current research projects to determine your suitability
Phone: (03) 9623 9439
Email: trials@skinhealthinstitute.org.au

Donate